Director at Design Therapeutics (DSGN) awarded 30,000 stock options

Rhea-AI Filing Summary

Design Therapeutics, Inc. director Heather A. Berger received a grant of stock options covering 30,000 shares of Common Stock at an exercise price of $10.55 per share. These options now represent 30,000 derivative securities held directly after the transaction.

The options vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders, aligning vesting with ongoing board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Berger Heather A.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 30,000 shares Exercise price: $10.55 per share Post-transaction derivative holdings: 30,000 options +2 more

5 metrics

Stock options granted 30,000 shares Grant to director Heather A. Berger

Exercise price $10.55 per share Stock option strike price

Post-transaction derivative holdings 30,000 options Total derivative securities after grant

Option expiration date June 8, 2036 Option term end date

Vesting schedule 12 monthly installments Over 12 months following June 9, 2026

Key Terms

Stock Option (right to buy), Common Stock, Vesting in equal monthly installments, Annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title is reported as Stock Option (right to buy) for the director"

Common Stock financial

"Each option is exercisable into shares of Common Stock of the issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Vesting in equal monthly installments financial

"The shares subject to the option vest in equal monthly installments over 12 months"

Annual meeting of stockholders financial

"Options will in any case be fully vested on the date of the Company’s next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berger Heather A.

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CALIFORNIA 92011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.55	06/09/2026		A		30,000		(1)	06/08/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

	/s/ Mustapha Parekh, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Heather A. Berger report in this Design Therapeutics (DSGN) Form 4?

Heather A. Berger reported receiving a grant of stock options for 30,000 shares of Design Therapeutics common stock. The options were awarded at a $10.55 exercise price and represent compensation for her role as a director.

How many Design Therapeutics (DSGN) shares are covered by the new stock options?

The new stock option grant covers 30,000 shares of Design Therapeutics common stock. These derivative securities give the director the right to buy the shares at a fixed $10.55 exercise price if and when the options are exercised.

What is the exercise price of Heather A. Berger’s Design Therapeutics (DSGN) options?

The stock options were granted with an exercise price of $10.55 per share. This means Berger can buy up to 30,000 shares of Design Therapeutics common stock at $10.55 once the options vest and are exercised.

How do the Design Therapeutics (DSGN) director’s options vest over time?

The options vest in equal monthly installments over 12 months following June 9, 2026. However, they will in any case be fully vested on the date of Design Therapeutics’ next annual meeting of stockholders, whichever occurs first.

How many Design Therapeutics (DSGN) derivative securities does Heather A. Berger hold after this grant?

Following the reported transaction, Heather A. Berger holds stock options representing 30,000 derivative securities. These options each relate to one share of Design Therapeutics common stock, subject to vesting and future exercise by the director.